Neuroprotection and stroke: time for a compromise.
In April 2007, there existed a repertory of 286 trials concerned with acute ischemic stroke on the Stroke Trials Registry (http://www.strokecenter.org/trials/), of which 209 trials were considered as complete (with no evidence of patient benefit unless one considers the much hard fought for and modest results of the tPA studies). Among other questions arising from such failures, one can wonder whether the plethora of pharmacological agents that exhibited neuroprotective properties in pre-clinical studies were selected for clinical trials entirely based upon their experimental efficacy. This mini-review will try to point out some of the weaknesses that could underline the failure of both researchers and clinicians involved in the field of stroke to obtain their ultimate goal--brain protection.
Young
Alan R
AR
INSERM-Avenir, tPA in the working brain, GIP CYCERON, University of Caen, Caen, France.
Ali
Carine
C
Duretête
Arnaud
A
Vivien
Denis
D
D000818:Animals; D002986:Clinical Trials as Topic / Q000639:trends; D006801:Humans; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D020521:Stroke / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D015912:Thrombolytic Therapy / Q000379:methods / Q000639:trends
D018696:Neuroprotective Agents